Iaso Biotherapeutics Co. Ltd. has established new collaborations with Umoja Biopharma Inc. for the development and commercialization of novel ex vivo and in vivo cell and gene therapies. These collaborations seek to advance off-the-shelf cell and gene therapies with applications in oncology and immunology.
Radiotherapy resistance and metastasis are among the top risk factors for refractory oral squamous cell carcinoma (OSCC), the mechanisms of which must be elucidated, plus there is a lack of biomarkers to predict response.
Remix Therapeutics Inc. has closed a $60 million financing to advance its lead program, REM-422, into the clinic and for further advancement of a pipeline of RNA processing targeted therapeutics.
Researchers from Baylor University and collaborators have described the synthesis and evaluation of a series of 6-aryl-3-aroyl-indole analogues acting as tubulin polymerization inhibitors aimed to be used as anticancer agents. Inhibitors of tubulin polymerization are promising antiproliferative agents and their interaction with the colchicine site is linked to its activity as vascular disrupting agents (VDAs).
Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) compounds comprising a cereblon (CRBN) binding moiety covalently bonded to a B-cell lymphoma 6 protein (BCL6) targeting moiety through a linker reported to be useful for the treatment of cancer.
Mirati Therapeutics Inc. has identified compounds acting as GTPase KRAS and/or GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers at Aston Science Co. Ltd. and Korea Research Institute of Chemical Technology have synthesized phenylsulfonamide derivatives acting as eukaryotic translation initiation factor 2-α kinase 1 (HRI) and/or translation initiation factor 2-α kinase 3 (PERK) and/or eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.
Guangzhou Fermion Technology Co. Ltd. has disclosed non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of cancer, asthma and more.
About 30% of patients with acute myeloid leukemia (AML) harbor mutations in the gene encoding receptor-type tyrosine-protein kinase FLT3 in the form of internal tandem duplication (ITD) or mutations in the tyrosine kinase domain.
Allorion Therapeutics Inc. has entered into an exclusive option and global license agreement with Astrazeneca plc to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor.
RSS
